We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
- Authors
Menghini, Rossella; Casagrande, Viviana; Rizza, Stefano; Federici, Massimo
- Abstract
Hyperglycemia strongly affects endothelial function and activation, which in turn increases the risk of atherosclerotic cardiovascular disease. Among pharmacotherapies aimed at lowering blood glucose levels, glucagon-like peptide 1 receptor agonists (GLP-1RA) represent a class of drugs involved in the improvement of the endothelium damage and the progression of cardiovascular diseases. They show antihypertensive and antiatherosclerotic actions due at least in part to direct favorable actions on the coronary vascular endothelium, such as oxidative stress reduction and nitric oxide increase. However, cumulative peripheral indirect actions could also contribute to the antiatherosclerotic functions of GLP-1/GLP-1R agonists, including metabolism and gut microbiome regulation. Therefore, further research is necessary to clarify the specific role of this drug class in the management of cardiovascular disease and to identify specific cellular targets involved in the protective signal transduction. In the present review, we provide an overview of the effects of GLP-1RAs treatment on cardiovascular disease with particular attention on potential molecular mechanisms involving endothelium function on formation and progression of atherosclerotic plaque.
- Subjects
ENDOTHELIUM diseases; CARDIOVASCULAR diseases; PEPTIDE receptors; GLUCAGON-like peptide 1; ENDOTHELIUM; VASCULAR endothelium; ATHEROSCLEROTIC plaque
- Publication
Acta Diabetologica, 2023, Vol 60, Issue 11, p1441
- ISSN
0940-5429
- Publication type
Article
- DOI
10.1007/s00592-023-02124-w